Sukhmani K. Padda, MD
5.0
7 Reviews
310-423-0377
Fax: 310-423-4759
5.0
7 Reviews
Sukhmani K. Padda, MD
Scheduling
In person visits
Fax: 310-423-4759
Samuel Oschin Cancer Center
127 S San Vicente Blvd - 7th Floor
Los Angeles, CA
34.074713 -118.379418From You
5.0
7 Reviews
Sukhmani K. Padda, MD
Gender
Female
Locations
Experience
Specialties
Area in which a healthcare provider is highly trained and often board certified.
1
- IM Hematology Oncology
Sub Specialties
A focused area of clinical knowledge and skills within a specialty. Example: a neurology specialist focused on stroke treatment.
1
- Thoracic Medical Oncology
Programs
Cedars-Sinai clinical programs this provider is part of:
3
Research Areas
Titles
- Associate Professor, Medicine
- Director, Thoracic Medical Oncology
Education & Training
-
Northeast Ohio Medical University, 2007
Medical School
-
Internal Medicine, Stanford University, 2011
Residency
-
Medical Hematology/Oncology, Stanford University, 2014
Fellowship
Achievements
-
2
Board Certifications
-
7
Awards and Honors
-
6
Publications
Board Certifications
-
IM/Oncology
American Board of Internal Medicine
-
General Internal Medicine
American Board of Internal Medicine
Awards and Honors
- NorCal CarciNET Community Travel Award, 9th Annual Multidisciplinary Neuroendocrine Tumor Symposium, 2016
- Chair, International Association for the Study of Lung Cancer (IASLC) Career Development/Fellowship Committee, 2019
- Elected Councilor, International Thymic Malignancy Interest Group Steering Committee, 2017-2019
- Stanford Cancer Institute Fellowship Award, 2014-2015
- American Society of Clinical Oncology (ASCO)/American Association for Cancer Research (AACR) Workshop: Methods in Clinical Cancer Research, 2013
- Department of Medicine Teaching Award, Stanford University, Stanford, CA, 2019
- Society of Immunotherapy for Cancer (SITC) Travel Award, 2016
Publications
- Padda SK, Aredo JV, Vali S; Singh NK, Vasista SM, Kumar A, Neal JW, Abbasi, T, Wakelee HA. Computational Biological Modeling Identifies PD-(L)1 Immunotherapy Sensitivity Among Molecular Subgroups of KRAS-Mutated Non–Small-Cell Lung Cancer. DOI: 10.1200/PO.20.00172 JCO Precision Oncology no. 5 (2021) 153-162. Published online January 12, 2021.Morgensztern D, Rose M, Waqar SN, Morris J, Ma PC, Reid T, Brzezniak CE, Zeman KG, Padmanabhan A, Hirth J, I Spira A, Trepel JB, Padda SK. RRx-001 followed by platinum plus etoposide in patients with previously treated small-cell lung cancer. Br J Cancer. 2019 Jul;121(3):211-217.
- Padda SK, Yao X, Antonicelli A, Riess JW, Shang Y, Shrager JB, Korst R, Detterbeck F, Huang J, Burt BM, Wakelee HA, Badve SS. Paraneoplastic Syndromes and Thymic Malignancies: An Examination of the International Thymic Malignancy Interest Group Retrospective Database. J Thorac Oncol. 2018 Mar;13(3):436-446.
- Nabet BY, Esfahani MS, Moding EJ, Hamilton EG, Chabon JJ, Rizvi H, Steen CB, Chaudhuri AA, Liu CL, Hui AB, Almanza D, Stehr H, Gojenola L, Bonilla RF, Jin MC, Jeon YJ, Tseng D, Liu C, Merghoub T, Neal JW, Wakelee HA, Padda SK, Ramchandran KJ, Das M, Plodkowski AJ, Yoo C, Chen EL, Ko RB, Newman AM, Hellmann MD, Alizadeh AA, Diehn M. Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition. Cell. 2020 Oct 15;183(2):363-376.e13.
- Singh S, Bergsland EK, Card CM, Hope TA, Kunz PL, Laidley DT, Lawrence B, Leyden S, Metz DC, Michael M, Modahl LE, Myrehaug S, Padda SK, Pommier RF, Ramirez RA, Soulen M, Strosberg J, Sung A, Thawer A, Wei B, Xu B, Segelov E. CommNETs/NANETS guidelines for the diagnosis and management of patients with Lung Neuroendocrine Tumors: An international collaborative endorsement and update of the 2015 ENETS expert consensus guidelines. J Thorac Oncol. 2020 Jul 11:S1556-0864(20)30548-7.
- Sikic BI, Lakhani N, Patnaik A, Shah SA, Chandana SR, Rasco D, Colevas AD, O'Rourke T, Narayanan S, Papadopoulos K, Fisher GA, Villalobos V, Prohaska SS, Howard M, Beeram M, Chao MP, Agoram B, Chen JY, Huang J, Axt M, Liu J, Volkmer JP, Majeti R, Weissman IL, Takimoto CH, Supan D, Wakelee HA, Aoki R, Pegram MD, Padda SK. First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers. J Clin Oncol. 2019 Apr 20;37(12):946-953.
- Padda SK, Riess JW, Schwartz EJ, Tian L, Kohrt HE, Neal JW, West RB, Wakelee HA. Diffuse high intensity PD-L1 staining in thymic epithelial tumors. J Thorac Oncol. 2015 Mar;10(3):500-8.